XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes Sells 21,881 Shares

XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

XOMA Stock Up 0.6 %

NASDAQ XOMA opened at $29.88 on Friday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 1-year low of $14.33 and a 1-year high of $33.78. The company has a 50 day moving average of $28.66 and a 200-day moving average of $26.86.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $11.09 million during the quarter, compared to analyst estimates of $8.37 million. As a group, equities research analysts expect that XOMA Co. will post -0.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $117.00 price objective on shares of XOMA in a research report on Wednesday, October 23rd.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after acquiring an additional 1,968 shares during the last quarter. Ellsworth Advisors LLC bought a new position in XOMA in the third quarter valued at approximately $516,000. Rhumbline Advisers increased its stake in XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in XOMA in the first quarter valued at approximately $212,000. Finally, BNP Paribas Financial Markets increased its stake in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,266 shares during the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.